Ken Griffin Eagle Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$4.26 - $6.51 $120,004 - $183,386	-28,170 Reduced 39.18%	43,729 $229,000
Q4 2023 Feb 14, 2024	SELL	$4.63 - $15.21 $1.02 Million - $3.35 Million	-220,261 Reduced 75.39%	71,899 $376,000
Q3 2023 Nov 14, 2023	SELL	$15.21 - $22.88 $1.54 Million - $2.32 Million	-101,389 Reduced 25.76%	292,160 $4.61 Million
Q2 2023 Aug 14, 2023	BUY	$17.74 - $31.87 $4.27 Million - $7.66 Million	240,445 Added 157.05%	393,549 $7.65 Million
Q1 2023 May 15, 2023	BUY	$25.06 - $34.09 $987,439 - $1.34 Million	39,403 Added 34.65%	153,104 $4.34 Million
Q4 2022 Feb 14, 2023	SELL	$24.98 - $39.77 $1.78 Million - $2.84 Million	-71,360 Reduced 38.56%	113,701 $3.32 Million
Q3 2022 Nov 14, 2022	BUY	$26.42 - $47.12 $3.16 Million - $5.64 Million	119,741 Added 183.31%	185,061 $4.89 Million
Q2 2022 Aug 15, 2022	BUY	$41.26 - $51.35 $716,232 - $891,384	17,359 Added 36.19%	65,320 $2.9 Million
Q1 2022 May 16, 2022	BUY	$44.58 - $52.6 $1.2 Million - $1.41 Million	26,856 Added 127.25%	47,961 $2.37 Million
Q4 2021 Feb 14, 2022	SELL	$45.82 - $56.9 $1.14 Million - $1.42 Million	-24,989 Reduced 54.21%	21,105 $1.07 Million
Q3 2021 Nov 15, 2021	SELL	$43.79 - $55.78 $149,849 - $190,879	-3,422 Reduced 6.91%	46,094 $2.57 Million
Q2 2021 Aug 16, 2021	SELL	$36.86 - $44.5 $1.48 Million - $1.78 Million	-40,061 Reduced 44.72%	49,516 $2.12 Million
Q1 2021 May 17, 2021	SELL	$40.32 - $50.97 $5.86 Million - $7.41 Million	-145,422 Reduced 61.88%	89,577 $3.74 Million
Q4 2020 Feb 16, 2021	SELL	$41.72 - $51.34 $3.71 Million - $4.57 Million	-88,957 Reduced 27.46%	234,999 $10.9 Million
Q3 2020 Nov 16, 2020	BUY	$37.02 - $51.28 $4.74 Million - $6.57 Million	128,078 Added 65.39%	323,956 $13.8 Million
Q2 2020 Aug 14, 2020	BUY	$43.24 - $55.02 $8.13 Million - $10.3 Million	188,085 Added 2413.51%	195,878 $9.4 Million
Q1 2020 May 15, 2020	BUY	$34.37 - $60.07 $144,250 - $252,113	4,197 Added 116.71%	7,793 $358,000
Q4 2019 Feb 14, 2020	SELL	$54.32 - $64.31 $2.65 Million - $3.14 Million	-48,801 Reduced 93.14%	3,596 $216,000
Q3 2019 Nov 14, 2019	SELL	$53.25 - $59.98 $18,690 - $21,052	-351 Reduced 0.67%	52,397 $2.96 Million
Q2 2019 Aug 14, 2019	SELL	$46.61 - $58.45 $897,522 - $1.13 Million	-19,256 Reduced 26.74%	52,748 $2.94 Million
Q1 2019 May 15, 2019	BUY	$38.66 - $51.82 $1.25 Million - $1.68 Million	32,419 Added 81.9%	72,004 $0
Q4 2018 Feb 14, 2019	SELL	$36.72 - $67.73 $9.51 Million - $17.5 Million	-258,954 Reduced 86.74%	39,585 $1.59 Million
Q3 2018 Nov 13, 2018	BUY	$66.65 - $83.86 $1.72 Million - $2.16 Million	25,733 Added 9.43%	298,539 $0
Q2 2018 Aug 10, 2018	SELL	$51.25 - $76.62 $5.02 Million - $7.51 Million	-97,990 Reduced 26.43%	272,806 $0
Q1 2018 May 11, 2018	BUY	$52.16 - $66.86 $15.5 Million - $19.8 Million	296,327 Added 397.92%	370,796 $19.5 Million
Q4 2017 Feb 09, 2018	BUY	$49.6 - $60.87 $3.69 Million - $4.53 Million	74,469	74,469 $3.98 Million

Others Institutions Holding EGRX

# of Institutions

Shares Held

9.89M

Call Options Held

1.01M

Put Options Held

Nantahala Capital Management, LLC New Canaan, CT

1.96M
Shares

$7.75 Million
0.73% of portfolio
Aigh Capital Management LLC Baltimore, MD

1.21M
Shares

$4.79 Million
2.46% of portfolio
Citigroup Inc

1M
Shares

$3.96 Million
0.0% of portfolio
Aqr Capital Management LLC Greenwich, CT

697K
Shares

$2.75 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

564K
Shares

$2.23 Million
0.0% of portfolio

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $51.4M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account